Epithelial cells and Rhinovirus
Infecting tumor cells with viruses to provoke an immune response used to be  termed (tumor / immune ) 'xenogenization'.  The approach may now fall under the general headings of tumor immunology, immune modifiers or tumor vaccines.   Xenogenization been explored for decades (with only moderate success).  Some modern approaches include adding immune stimulating genes to the viral 'vector' (e.g GM-CSF) to try and improve an immune response.  Xenogenization is usually intended for use with the patients own (autologous) tumor cells.   Other approaches that use viruses include delivering genes that preferentially act in tumor cells or "tumor antigens".  Some of these modified viruses may have been engineered to have low, or no, ability to replicate in the body.   Note that some viruses, such as influenza or rhinoviruses are not (generally) able to circulate in the bloodstream (viremia) to infect distant tumor cells.  Instead, the goal of using such viruses is to provoke an immune response against tumor antigens expressed on the 'original infected' cells at the site of injection and hope that the immune system goes on to attack distant masses/metastases.